The healthcare industry is always evolving, and new therapies drive ongoing growth over and above the growth from the ageing demographic. However, it’s important that investors recognise that the sector’s growth doesn’t necessarily translate equally to each participant, for example, when new therapies displace incumbents. Three particular drivers of change... Show More
In a somewhat unusual outcome, Sonic Healthcare (ASX:SHL) was a beneficiary of regulatory change in Australia in May. Your local GP, if they have a pathology lab on site, has likely been receiving rent for its pathology room well above the going market rate for similar space. The Federal Government... Show More
Sonic 1H16 results were in line with our expectations, with solid underlying earnings growth driven by ex-Australia ops, somewhat overcoming well-flagged government policies that negatively impacted domestic businesses. Importantly, strong organic laboratory growth, profit enhancements across the domestic front, and gains from recent acquisitions and FX tailwinds, reiterate the outlook... Show More
Primary Health Care's (ASX: PRY) share price has fallen 54% since we rang the Avoid bell. Is it worth a second look? Show More
Sonic FY15 results were in-line with our expectations, with solid top-line growth constrained by well-flagged challenging market conditions in both Australia and US pathology flat-lining underlying profit. However, we believe the worst is behind us, as strengthening 2H organic volume growth across all regions, a restructured US business, along with... Show More
Disruption on the way for Sonic Healthcare. Sonic is the largest pathology company in Australia and Germany, and the third largest in the US. The business generated $3.5 billion in revenue and $340 million in NPAT in 2013 and employs thousands of pathologists, medical scientists and technicians. You wouldn't think... Show More
Sonic Healthcare SHL has been trading in an up trend over the past ten months, which remains technically intact. Recent price action decisively broke above resistance of $16.32, confirming an ascending triangle. The pattern has bullish implications and suggests that higher prices are likely to unfold over the medium term.... Show More